Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: The impact of inflammatory process and oxidative stress

Atherosclerosis

Volumn 214, Issue 1, 2011, Pages 151-157

  Tousoulis, Dimitris ^a   Andreou, Ioannis ^a   Tsiatas, Marinos ^a   Miliou, Antigoni ^a   Tentolouris, Costas ^a   Siasos, Gerasimos ^a   Papageorgiou, Nikos ^a   Papadimitriou, Christos A ^a   Dimopoulos, Meletios Athanasios ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Endothelial progenitor cells; Heart failure; Myeloperoxidase; Statins; Xanthine oxidase inhibitors

Indexed keywords

ALLOPURINOL; PLACEBO; ROSUVASTATIN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR FUNCTION; CONGESTIVE HEART FAILURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC HEART FAILURE;

AGED; ALLOPURINOL; ANTIGENS, CD; ANTIGENS, CD34; ENDOTHELIAL CELLS; ENZYME INHIBITORS; FEMALE; FLUOROBENZENES; GLYCOPROTEINS; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PEPTIDES; PEROXIDASE; PYRIMIDINES; STEM CELLS; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XANTHINE OXIDASE;

EID: 78650827558     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.11.002     Document Type: Article

References (39)

1. Walter D.H., Rittig K., Bahlmann F.H., et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002, 105:3017-3024.
2. Takahashi T., Kalka C., Masuda H., et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999, 5:434-438.
3. Jujo K., Ii M., Losordo D.W. Endothelial progenitor cells in neovascularization of infarcted myocardium. J Mol Cell Cardiol 2008, 45:530-544.
4. Tousoulis D., Andreou I., Antoniades C., Tentolouris C., Stefanadis C. Role of inflammation and oxidative stress in endothelial progenitor cell function and mobilization: therapeutic implications for cardiovascular diseases. Atherosclerosis 2008, 201:236-247.
5. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001, 89:E1-7.
6. Hill J.M., Zalos G., Halcox J.P., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003, 348:593-600.
7. Schmidt-Lucke C., Rossig L., Fichtlscherer S., et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005, 111:2981-2987.
8. Werner N., Kosiol S., Schiegl T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005, 353:999-1007.
9. Node K., Fujita M., Kitakaze M., Hori M., Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003, 108:839-843.
10. Engberding N., Spiekermann S., Schaefer A., et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?. Circulation 2004, 110:2175-2179.
11. Tousoulis D., Antoniades C., Stefanadis C. Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques. Heart 2005, 91:553-558.
12. Andreou I., Tousoulis D., Tentolouris C., Antoniades C., Stefanadis C. Potential role of endothelial progenitor cells in the pathophysiology of heart failure: clinical implications and perspectives. Atherosclerosis 2006, 189:247-254.
13. Kissel C.K., Lehmann R., Assmus B., et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol 2007, 49:2341-2349.
14. Nonaka-Sarukawa M., Yamamoto K., Aoki H., et al. Circulating endothelial progenitor cells in congestive heart failure. Int J Cardiol 2007, 119:344-348.
15. Valgimigli M., Rigolin G.M., Fucili A., et al. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 2004, 110:1209-1212.
16. Theiss H.D., David R., Engelmann M.G., et al. Circulation of CD34+ progenitor cell populations in patients with idiopathic dilated and ischaemic cardiomyopathy (DCM and ICM). Eur Heart J 2007, 28:1258-1264.
17. Pelliccia F., Pasceri V., Cianfrocca C., et al. Endothelial progenitor cells in patients with coronary artery disease and left ventricular dysfunction. Coron Artery Dis 2009, 20:303-308.
18. Landmesser U., Engberding N., Bahlmann F.H., et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004, 110:1933-1939.
19. Leone A.M., Rutella S., Bonanno G., et al. Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J 2005, 26:1196-1204.
20. Schachinger V., Assmus B., Britten M.B., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004, 44:1690-1699.
21. Dimmeler S., Aicher A., Vasa M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001, 108:391-397.
22. Vasa M., Fichtlscherer S., Adler K., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001, 103:2885-2890.
23. Llevadot J., Murasawa S., Kureishi Y., et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001, 108:399-405.
24. Urbich C., Knau A., Fichtlscherer S., et al. FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells. FASEB J 2005, 19:974-976.
25. Assmus B., Urbich C., Aicher A., et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003, 92:1049-1055.
26. Urbich C., Dernbach E., Zeiher A.M., Dimmeler S. Double-edged role of statins in angiogenesis signaling. Circ Res 2002, 90:737-744.
27. Fadini G.P., Albiero M., Boscaro E., et al. Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells. Cell Biol Int 2010, 34:709-715.
28. Shimada T., Takeshita Y., Murohara T., et al. Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse. Circulation 2004, 110:1148-1155.
29. Landmesser U., Bahlmann F., Mueller M., et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005, 111:2356-2363.
30. Moiseeva O.M., Karelkina E.V., Moroshkin V.S., Seliutin A.V., Shliakhto E.V. Effect of therapy with rosuvastatin on circulating endothelial progenitor cells in patients with chronic heart failure. Kardiologiia 2009, 49:11-15.
31. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129-1135.
32. Aicher A., Heeschen C., Mildner-Rihm C., et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003, 9:1370-1376.
33. Landmesser U., Spiekermann S., Dikalov S., et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002, 106:3073-3078.
34. Houston M., Estevez A., Chumley P., et al. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem 1999, 274:4985-4994.
35. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261.
36. The GISSI-HF Investigators Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231-1239.
37. Cleland J.G., McMurray J.J., Kjekshus J., et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009, 54:1850-1859.
38. McMurray J.J., Kjekshus J., Gullestad L., et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009, 120:2188-2196.
39. Fadini G.P., Baesso I., Albiero M., et al. Technical notes on endothelial progenitor cells: ways to escape from the knowledge plateau. Atherosclerosis 2008, 197:496-503.